Citadel Advisors
EPRS

Citadel Advisors’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Citadel Advisors’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$3K – 9325
2015
Q4 		$3K Buy
+1,000
New +$4.51K ﹤0.01% 8567
2015
Q3 		– Sell
-100
Closed -$1K – 9745
2015
Q2 		$1K Buy
+100
New +$682 ﹤0.01% 8682

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's EPRS Position: Q2 2016 in Review

Citadel Advisors sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 10,359 shares — an estimated $28K sold.

Citadel Advisors first reported a position in EPRS in Q2 2015 and held it in 3 quarters. The position peaked at $230K in Q2 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

  • Citadel Advisors reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Citadel Advisors sold 10,359 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $28K.
  • Citadel Advisors first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q2 2015 and held it in 3 quarters.
  • Citadel Advisors's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $230K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.